A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Renaissance Technologies LLC holds 243,800 shares of AVXL stock, worth $2.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
243,800
Previous 466,437 47.73%
Holding current value
$2.1 Million
Previous $1.97 Million 29.67%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$4.11 - $7.04 $915,038 - $1.57 Million
-222,637 Reduced 47.73%
243,800 $1.38 Million
Q2 2024

Aug 09, 2024

BUY
$3.39 - $5.02 $1.31 Million - $1.94 Million
386,537 Added 483.78%
466,437 $1.97 Million
Q1 2024

May 13, 2024

BUY
$4.55 - $6.75 $363,545 - $539,325
79,900 New
79,900 $407,000
Q3 2022

Nov 14, 2022

BUY
$8.9 - $12.86 $82,770 - $119,598
9,300 Added 2.6%
367,100 $3.79 Million
Q2 2022

Aug 12, 2022

BUY
$7.31 - $12.84 $2.62 Million - $4.59 Million
357,800 New
357,800 $3.58 Million
Q1 2021

May 13, 2021

SELL
$5.17 - $16.13 $326,227 - $1.02 Million
-63,100 Closed
0 $0
Q4 2020

Feb 10, 2021

BUY
$4.01 - $7.58 $253,031 - $478,298
63,100 New
63,100 $341,000
Q2 2020

Aug 13, 2020

SELL
$2.62 - $5.2 $1.07 Million - $2.12 Million
-407,400 Closed
0 $0
Q1 2020

May 14, 2020

BUY
$2.38 - $5.81 $775,544 - $1.89 Million
325,859 Added 399.63%
407,400 $1.28 Million
Q4 2019

Feb 13, 2020

BUY
$2.31 - $3.14 $188,359 - $256,038
81,541 New
81,541 $211,000
Q1 2019

May 14, 2019

SELL
$1.68 - $3.42 $30,423 - $61,932
-18,109 Closed
0 $0
Q4 2018

Feb 13, 2019

BUY
$1.25 - $2.75 $22,636 - $49,799
18,109 New
18,109 $28,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $673M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.